Valeant Pharmaceuticals International (NYSE:VRX) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.
Valeant Pharmaceuticals International Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased 124.14% to $1.30 in the quarter versus EPS of $0.58 in the year-earlier quarter.
Revenue: Rose 24.75% to $1.07 billion from the year-earlier quarter.
Actual vs. Wall St. Expectations: Valeant Pharmaceuticals International reported adjusted EPS income of $1.30 per share. By that measure, the company beat the mean analyst estimate of $1.25. It beat the average revenue estimate of $297.08 million.
Quoting Management: “Despite a slow January due to the integration of the Valeant and Medicis sales organizations, we delivered another solid quarter of strong growth in Cash EPS and adjusted cash flow to our shareholders,” stated J. Michael Pearson, chairman and chief executive officer. “We were particularly pleased with the strong organic growth of our emerging market segment, which was primarily driven by Poland, Russia, Brazil, South East Asia, and South Africa, as well as the continued growth in many of our promoted brands.”
Key Stats (on next page)…